Tue, October 11, 2011
[ Tue, Oct 11th 2011 ] - Market Wire
Aetna??Michael Elliott???????
Mon, October 10, 2011
Sun, October 9, 2011
Sat, October 8, 2011
Fri, October 7, 2011
Thu, October 6, 2011
Wed, October 5, 2011
Tue, October 4, 2011
Mon, October 3, 2011
[ Mon, Oct 03rd 2011 ] - Market Wire
Medwell Capital to Adopt IFRS
Sun, October 2, 2011
Sat, October 1, 2011
Fri, September 30, 2011
Thu, September 29, 2011
Wed, September 28, 2011
Tue, September 27, 2011
Mon, September 26, 2011
Sat, September 24, 2011
Fri, September 23, 2011
Thu, September 22, 2011
Wed, September 21, 2011
Tue, September 20, 2011
Mon, September 19, 2011
Sun, September 18, 2011
Sat, September 17, 2011
Fri, September 16, 2011
Thu, September 15, 2011
Wed, September 14, 2011

Derma Sciences to Present at the Jefferies 2011 Global Healthcare Conference


//health-fitness.news-articles.net/content/2011/ .. jefferies-2011-global-healthcare-conference.html
Published in Health and Fitness on Monday, September 26th 2011 at 6:28 GMT by Market Wire   Print publication without navigation


PRINCETON, N.J.--([ BUSINESS WIRE ])--Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care announced today that the Company will be presenting at the Jefferies 2011 Global Healthcare Conference on Tuesday, September 27, 2011 at 5:00 p.m. BST (Noon EDT). The conference is being held September 27-28, 2011 at the Waldorf Hilton Hotel in London, United Kingdom. Edward J. Quilty, Chairman and CEO, will deliver the Company's corporate presentation.

The presentation will be webcast live at [ http://wsw.com/webcast/jeff62/dsci/ ] and on the Investor Relations section of the Company's website at [ www.dermasciences.com ], where it will also be archived for 90 days.

Derma Sciences is a medical technology company focused on the wound care marketplace, addressing; traditional dressings, advanced wound care dressings, and pharmaceutical wound care products. Its MEDIHONEY product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of indications, and was the focus of a positive large-scale, randomized controlled trial involving 108 subjects with leg ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB for better management of wound exudate, and BIOGUARD for infection prevention. Derma Sciences has successfully completed a Phase 2 clinical trial in diabetic foot ulcer healing with DSC127, a novel pharmaceutical drug under development for accelerated wound healing and scar reduction.

For more information please visit [ www.dermasciences.com ].


Publication Contributing Sources